<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Management of gynecologic issues in women with breast cancer.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Obstetricians and Gynecologists (ACOG). Management of gynecologic issues in women with breast cancer. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2012 Mar. 17 p.&amp;nbsp;(ACOG practice bulletin; no. 126).&amp;nbsp; [166 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Diaphragm for contraceptive use "/><FieldValue Value="ICD9CM: Bone mineral density studies  (88.98); Encounter for fertility preservation counseling  (V26.42); Infertility, female, of unspecified origin  (628.9); Malignant neoplasm of breast (female), unspecified  (174.9); Osteoporosis, unspecified  (733.00); Unspecified psychosexual disorder  (302.9)"/><FieldValue Value="MSH: Amines ; Biopsy ; Breast Neoplasms ; Clonidine ; Condoms ; Contraception ; Contraceptive Devices, Female ; Contraceptives, Oral, Hormonal ; Counseling ; Cyclohexanecarboxylic Acids ; Diphosphonates ; gamma-Aminobutyric Acid ; Infertility, Female ; Intrauterine Devices ; Intrauterine Devices, Copper ; Life Style ; Menopause ; Osteoporosis ; Osteoporotic Fractures ; Raloxifene ; Risk Assessment ; Risk Factors ; Serotonin Uptake Inhibitors ; Sexual Dysfunction, Physiological ; Sexual Dysfunctions, Psychological ; Sterilization, Reproductive ; Tamoxifen ; Ultrasonography "/><FieldValue Value="MTH: Amines ; Biopsy ; Bone Mineral Density Test ; Condoms, Male ; Contraceptive methods ; Counseling ; Diphosphonates ; Endometrial biopsy ; Female infertility ; Female sexual dysfunction ; gabapentin ; Intrauterine Devices ; Life Style ; Malignant neoplasm of female breast ; Mammary Neoplasms ; Menopause ; Osteoporosis ; Physiological Sexual Disorders ; Psychosexual Disorders ; Risk Assessment ; risk factors ; Selective Serotonin Reuptake Inhibitors ; Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) ; Serotonin Uptake Inhibitors ; Sexual Dysfunction ; Sexual sterilization ; Tamoxifen ; Ultrasonography ; Vaginal contraceptive diaphragm (device) "/><FieldValue Value="PDQ: biopsies ; clonidine ; gabapentin ; menopausal symptoms ; osteoporosis ; raloxifene ; ultrasonography "/><FieldValue Value="SNOMEDCT_US: Amine  (43201005); Atrophy of vagina  (297147009); Biopsy  (129314006); Biopsy  (86273004); Clonidine  (372805007); Clonidine  (62782004); Condom  (706506000); Contraception  (13197004); Contraceptive diaphragm  (20359006); Contraceptive diaphragm  (336704008); Contraceptive diaphragm  (469119008); Counseling  (129441002); Counseling  (409063005); Diphosphonate  (372907000); Diphosphonate  (96281001); Endometrial biopsy  (386802000); Female infertility  (6738008); Female sterilization  (169549004); Female sterilization  (60890002); Gabapentin  (108402001); Gabapentin  (386845007); Gamma-aminobutyric acid  (259100002); Intrauterine contraceptive device  (268460000); Life style  (134436002); Life style  (60134006); Malignant neoplasm of female breast  (372064008); Menopausal symptom  (21801002); Menopause  (161712005); Menopause  (198435007); Neoplasm of breast  (126926005); Osteoporosis  (64859006); Osteoporosis risk assessment done  (391014006); Osteoporotic fracture  (46675001); Psychosexual disorder  (56627002); Raloxifene  (109029006); Raloxifene  (419530003); Risk assessment  (225338004); Risk factor  (80943009); Selective serotonin re-uptake inhibitor  (349854005); Selective serotonin re-uptake inhibitor  (373225007); Sexual disorder  (225723003); Sexual disorder  (231532002); Sexual disorder  (56925008); Tamoxifen  (373345002); Tamoxifen  (75959001); Ultrasonography  (16310003); Ultrasonography  (278292003); Ultrasonography  (359659005); Ultrasonography of uterus  (79966006)"/><FieldValue Value="SPN: CONDOM ; DIAPHRAGM, CONTRACEPTIVE (AND ACCESSORIES) ; SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC "/><FieldValue Value="UMD: Condoms, Male  (18-080); Contraceptive Diaphragms  (13-005); Intrauterine Devices, Contraceptive  (12-156); Procedure Kit/Trays, Biopsy  (10-401); Scanning Systems, Ultrasonic  (14-278)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Gynecologic health issues related to breast cancer and breast cancer treatment, including menopausal symptoms, infertility, sexual function, contraceptive issues, and osteoporosis&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Oncology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To review the effect of breast cancer treatment on common women's health issues such as fertility, contraceptive management, menopause, sexual function, and osteoporosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide a rationale for follow-up and treatment of these gynecologic issues &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Women who have or have had breast cancer&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis risk assessment (clinical risk factors and bone marrow density testing and monitoring) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bisphosphonates and raloxifene for osteoporosis prevention and treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Counseling about lifestyle changes to reduce the risk of bone loss and osteoporotic fractures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and clonidine for vasomotor symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of nonhormonal methods for treatment of vaginal atrophy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine endometrial biopsy and uterine ultrasonography (not recommended for postmenopausal women taking tamoxifen without bleeding) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Contraceptive options: barrier methods, such as condoms and diaphragms, the copper intrauterine device, and sterilization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoidance of hormones for contraception &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Counseling on fertility and infertility, including potentially fertility-preserving options &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Rate of breast cancer treatment-related gynecologic adverse effects &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness of management strategies for treatment-related adverse effects &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between June 2010 and November 2011. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician&amp;ndash;gynecologists were used.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt; Evidence obtained from at least one properly designed randomized controlled trial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt; Evidence obtained from well-designed controlled trials without randomization.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt; Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt; Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Analysis of available evidence was given priority in formulating recommendations. When reliable research was not available, expert opinions from obstetrician-gynecologists were used. See also the &quot;Rating Scheme for the Strength of Recommendations&quot; field regarding Level C recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt; &amp;mdash; Recommendations are based on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt; &amp;mdash; Recommendations are based on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt; &amp;mdash; Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Practice Bulletins are validated by two internal clinical review panels composed of practicing obstetrician-gynecologists generalists and sub-specialists. The final guidelines are also reviewed and approved by the American College of Obstetricians and Gynecologists (ACOG) Executive Board.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grades of evidence (&lt;strong&gt;I-III&lt;/strong&gt;) and levels of recommendations (&lt;strong&gt;A-C&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The following recommendation and conclusion is based on good and consistent scientific evidence (Level A)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have both been shown to be safe and to reduce the severity of hot flushes in patients with breast cancer, although caution must be used when using these agents in conjunction with tamoxifen. Gabapentin and clonidine are other options for management of hot flushes. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The following recommendations and conclusions are based on limited or inconsistent scientific evidence (Level B)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The 2009 National Comprehensive Cancer Network Task Force report recommends that pharmacologic therapy should be considered for women with breast cancer who have T scores between -1.5 and -2.0. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine endometrial biopsy and uterine ultrasonography are not recommended for postmenopausal women taking tamoxifen without bleeding. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Contraceptive options for patients with breast cancer include barrier methods, such as condoms and diaphragms, the copper intrauterine device, and sterilization. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pregnancy after breast cancer is not thought to increase breast cancer recurrence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If future pregnancy is desired for women in whom breast cancer has been diagnosed, appropriate consultation with fertility specialists should be offered to ascertain whether immediate assisted reproductive strategies are possible to preserve fertility. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The following recommendation is based primarily on consensus and expert opinion (Level C)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Nonhormonal methods should be considered first-line treatment for vaginal atrophy in women with a history of hormone-sensitive breast cancer. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt; Evidence obtained from at least one properly designed randomized controlled trial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt; Evidence obtained from well-designed controlled trials without randomization.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt; Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt; Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt; &amp;mdash; Recommendations are based on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt; &amp;mdash; Recommendations are based on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt; &amp;mdash; Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of gynecologic health issues in women treated for breast cancer&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Bisphosphonates&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Very rare adverse effects associated with the long-term use of bisphosphonates have been suggested but not yet confirmed, including atypical femur fractures and osteonecrosis of the jaw. Although generally well tolerated, the adverse effects of raloxifene include vasomotor symptoms (hot flushes and night sweats) and an increased risk of thromboembolic events.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The optimal balance between effectiveness and adverse effects of venlafaxine (most commonly, dry mouth, nausea, constipation, and poor appetite) appears to be a dose of 75 mg, with larger doses associated with an increased likelihood of adverse effects with no further clinical benefit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There is some significant concern that the use of pure SSRIs in women taking tamoxifen may interfere with tamoxifen metabolism and thus block the drug's therapeutic benefit. This interference with tamoxifen appears to be less severe or nonexistent for SNRIs such as venlafaxine.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Gabapentin&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Adverse effects, including dizziness, are common.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ultrasound Surveillance&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In women taking tamoxifen, ultrasound surveillance has been associated with a significant false-positive rate because tamoxifen induces enlargement of the subendometrial glands, resulting in increased endometrial thickness, irregular echoes, and cystic changes; but, these findings do not correlate with malignant histology. In general, endometrial thickness alone should not be used as an indicator for intervention because it will lead to unnecessary invasive diagnostic procedures.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ovarian Stimulation for In Vitro Fertilization (IVF) Procedures&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One of the concerns with immediate IVF with embryo cryopreservation is whether the high levels of estrogen produced by ovarian stimulation will have adverse effects on breast cell proliferation. In the general infertility population, there are no convincing data that ovulation induction or IVF increases the risk of breast cancer. It is not known if the high estrogen milieu has any adverse effect on breast cancer that is already established.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is relatively contraindicated to use hormonal contraceptive options in patients with breast cancer. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of hormone therapy is generally contraindicated in patients with hormone-positive breast cancer. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Some oncologists have felt that conventional ovulatory stimulating agents are contraindicated; therefore, patients with breast cancer have previously been offered unstimulated or natural-cycle IVF, which has results in patients without cancer that may approach IVF pregnancy rates. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The information in this guideline is designed to aid practitioners in making decisions about appropriate obstetric and gynecologic care. These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Obstetricians and Gynecologists (ACOG). Management of gynecologic issues in women with breast cancer. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2012 Mar. 17 p.&amp;nbsp;(ACOG practice bulletin; no. 126).&amp;nbsp; [166 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012 Mar" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American College of Obstetricians and Gynecologists - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins&amp;mdash;Gynecology&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG) committees are created or abolished and their overall function defined by the Executive Board. Appointments are made for one year, with the understanding that such appointment may be continued for a total of three years. The majority of committee members are Fellows, but Junior Fellows also are eligible for appointment. Some committees may have representatives from other organizations when this is particularly appropriate to committee activities. The president elect appoints committee members annually.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: None available&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available for purchase from the American College of Obstetricians and Gynecologists (ACOG) Distribution Center, PO Box 933104, Atlanta, GA 31193-3104; telephone, 800-762-2264; e-mail: &lt;a href=&quot;mailto:sales@acog.org&quot;&gt;sales@acog.org&lt;/a&gt;. The ACOG Bookstore is available online at the &lt;a href=&quot;http://sales.acog.org/bookstore/&quot; title=&quot;ACOG Web site&quot;&gt;ACOG Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A proposed performance measure is included in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on April 3, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
